Mark Rogers-Evans
Hoffmann-La Roche
125 Papers
714 Citations
Mark Rogers-Evans is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Cannabinoid receptor type 2 & Chemistry. The author has an hindex of 24, co-authored 124 publications. Previous affiliations of Mark Rogers-Evans include ETH Zurich & Karolinska Institutet.
Chat about Author
Papers
Oxetanes as Versatile Elements in Drug Discovery and Synthesis
TL;DR: This Minireview gives an overview of the recent advances made in the preparation and use of 3-substituted oxetanes and includes a discussion of the site-dependent modifications of various physicochemical and biochemical properties that result from the incorporation of the oxetane unit in molecular architectures.
386
Oxetanes in Drug Discovery: Structural and Synthetic Insights
Georg Wuitschik,Erick M. Carreira,Björn Wagner,Holger Fischer,Isabelle Parrilla,Franz Schuler,Mark Rogers-Evans,Klaus Müller +7 more
TL;DR: A rich chemistry of oxetan-3-one and derived Michael acceptors provide venues for the preparation of a broad variety of novel oxetanes not previously documented, thus providing the foundation for their broad use in chemistry and drug discovery.
361
Development of a virtual screening method for identification of "frequent hitters" in compound libraries.
Olivier Roche,Petra Schneider,Jochen Zuegge,Wolfgang Guba,Manfred Kansy,Alexander Alanine,Konrad Bleicher,Franck Danel,Gutknecht Eva-Maria,Mark Rogers-Evans,Werner Neidhart,Henri Stalder,Michael Patrick Dillon,Eric Brian Sjogren,Nader Fotouhi,Paul Gillespie,Robert Alan Goodnow,Harris William,Phil Jones,Mikio Taniguchi,Shinji Tsujii,Wolfgang von der Saal,Gerd Zimmermann,Gisbert Schneider +23 more
TL;DR: A computer-based method was developed for rapid and automatic identification of potential "frequent hitters" that will be a valuable tool for the prioritization of compounds from large databases, for compound purchase and biological testing, and for building new virtual libraries.
269